OncLive® On Air cover image

S10 Ep40: FDA Approval Insights: Imetelstat in Lower-Risk MDS and Transfusion-Dependent Anemia

OncLive® On Air

00:00

FDA Approval Insights on Telomerase Inhibition in MDS

This chapter explores the FDA's approval of a telomerase inhibitor for lower-risk myelodysplastic syndromes, emphasizing results from the eMERGE trial. Notable findings include a 40% rate of transfusion independence and significant hemoglobin improvements among patients, demonstrating sustained efficacy.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app